Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

Abstract Introduction Taniborbactam (formerly VNRX-5133) is an investigational β-lactamase inhibitor in clinical development in combination with cefepime for the treatment of MDR Gram-negative pathogens. Objectives To assess the safety profile and pulmonary disposition of 2–0.5 g cefepime/taniborbac...

Full description

Bibliographic Details

Published in:	Journal of antimicrobial chemotherapy Vol. 78; no. 3; pp. 703 - 709
Main Authors:	Asempa, Tomefa E, Kuti, Joseph L, Nascimento, Jeffrey C, Pope, Samuel J, Salerno, Edward L, Troy, Patrick J, Nicolau, David P
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 02.03.2023
Subjects:	Adult Anti-Bacterial Agents - pharmacology Bronchoalveolar Lavage Fluid Cefepime - pharmacology Chromatography, Liquid Humans Tandem Mass Spectrometry
ISSN:	0305-7453, 1460-2091, 1460-2091
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!